RENO, Nev., April 12, 2011 /PRNewswire/ — Visual Healthcare
Corp. (the “Company”) (NASDAQ OTC: VSHC) announces today that work
has begun on a Chinese based adaptation of the information
technology grid that its clients use in their clinical trial
applications.
This project has been launched in response to requests from both
Chinese academic centers as well as Clinical Research Organization
experts responding to Chinese government resolve to create a major
domestic drug industry.
In 2007, the Chinese government had enacted a series of laws
designed to create significant incentives in order to foster a
fast-growth environment for the creation of a large scale
pharmaceutical sector. While actual drug manufacturing has been
growing, the complexities of running clinical trials according to
Western standards has proved a more difficult challenge.
Many U.S. based CROs intend to support Chinese efforts as they
see benefits from these developments such as the potential for off
shore clinical trials at much lower cost. China may prove to be
fertile ground for clinical trials with its large population which
may ease hurdles ranging from cost, patient recruitment delays,
patient compliance during participation, qualified professionals,
new clinical trial patients, and other problems.
“Operating pharmaceutical testing facilities and clinical trials
in China will require compatible software to manage their
information gathering and data mining procedures,” says Chairman
Gerard Dab. “Yes it is a new market and it has some challenges such
as conveying novel notions like informed consent but we
believe that we can leverage our Chinese experience to generate
significant business in helping this budding Chinese industry.”
Although health is provincial or local, the central government
now allocates special budgets to hospitals for acquisition of new
technology, a move that will help usher in modern clinical trials.
Another critical success
‘/>”/>
